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patient hospital records analysis for the years 1998–2000,
validated by expert panel opinion. The consensus method
used was a modiﬁed form of the Rand Version of the
Nominal Group Technique. For severity stages I/II and III
analysis was conducted for subgroups of patients accord-
ing to menopausal and estrogen/progesterone receptor
status. Results were reported in the form of “decision
analysis trees” for each patient group. Probability distri-
butions were based on the frequency of usage of each
treatment pathway. For Stage IV patients, analysis was
conducted regardless of menopausal and ER/PR status.
Clinical practice was reported at sequential lines of
patient management in frequency tables depicting usage
ratios of each therapeutic pathway. RESULTS: Treatment
appears more standardized for disease stages I, II, III. The
most frequently used therapy is surgery followed by
radiotherapy and adjuvant therapy. Stage III patients 
are more likely to receive neo-adjuvant therapy. ER/PR
status determines the choice of adjuvant therapy, as
patients with positive receptors are most likely to re-
ceive endocrine therapy alone or in combination with
chemotherapy. In Stage IV, observed treatment pathways
present varying sequential usage across patients, with sys-
temic chemotherapy, endocrine therapy and radiotherapy
as the most frequent clinical options. CONCLUSIONS:
The model seems a feasible approach in depicting current
clinical practice in Greece. It can be used as tool for clin-
icians and decision makers for monitoring health care
costs, estimating cost of illness, and evaluating the intro-
duction of new therapies in the management of Breast
Cancer patients in Greece.
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OBJECTIVE: To estimate the difference in total direct
cost between daily ﬁlgrastim injections versus a single
once-per-cycle pegﬁlgrastim injection over four cycles 
in France and Germany. METHOD: The perspective of
analysis was that of the national health care services. A
Markov model was used to estimate the total direct costs
for neutropenia management over four chemotherapy
cycles. Total costs included drug administration cost,
drug acquisition cost, patient monitoring cost and febrile
neutropenia (FN) management cost. Clinical data were
obtained from a meta-analysis of two pivotal, randomised
double-blind clinical trials comparing ﬁlgrastim and peg-
ﬁlgrastim [Siena S et al. Oncol Rep 2003;10:715–24.].
The drug administration cost and patient monitoring cost
were estimated using a time and motion method. The per
cycle drug administration cost for ﬁlgrastim and pegﬁl-
grastim was €155 and €14, respectively, in France and
€530 and €67 in Germany. The per cycle drug acquisition
cost for ﬁlgrastim and pegﬁlgrastim was assumed equal
in both countries. In France, the per cycle monitoring cost
for ﬁlgrastim and pegﬁlgrastim was €43 and €22, com-
pared to €31 and €15 in Germany. The cost for manag-
ing FN in France was €2439 per episode and €1816 in
Germany. RESULTS: In both countries, a once-per-cycle
pegﬁlgrastim injection was less expensive than daily injec-
tions of ﬁlgrastim. The mean total cost for neutropenia
management with ﬁlgrastim and pegﬁlgrastim was, re-
spectively, €6056 and €5213 over 4 chemotherapy cycles
in France, and €6449 and €4850 in Germany. The dif-
ference was mainly due to a lower FN rate in the pegﬁl-
grastim group [11% vs. 19% in the ﬁlgrastim arm (p <
0.05)] and a lower drug administration cost. CONCLU-
SION: Compared to ﬁlgrastim, the use of pegﬁlgrastim
reduced the total cost for neutropenia management in
France and Germany.
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OBJECTIVES: The objectives of this retrospective data-
base study were to estimate the treatment costs for bone
fractures in older women (aged 65 years and older) who
have early breast cancer and to compare those costs with
the treatment costs for bone fractures incurred by older
women who do not have breast cancer. METHODS:
Direct costs for bone fractures in early breast cancer
patients were evaluated using the Medicare 5% sample
data (1997–1998), including the estimation of “medical
treatment costs for bone fracture,” “excess treatment
costs for bone fracture,” and “excess LTC costs for bone
fracture.” Inpatient costs, medical treatment costs, and
LTC admission rates were compared between a cohort of
women with early breast cancer and bone fracture and an
age-matched cohort of normal women with bone frac-
ture, stratiﬁed by age group, status of hospitalization for
bone fracture, and type of bone fracture. RESULTS: For
older women with early breast cancer, the “direct cost for
bone fracture” was estimated to be about $45,579, 57%
of which is for treatment costs of the bone fracture
(including 32% of inpatient hospital costs and 25% of
non-inpatient hospital costs), 24% for other excess treat-
ment costs, and 18% for excess long-term care costs.
CONCLUSIONS: This study represents the ﬁrst research
on the costs of bone fracture in older women with early
breast cancer. It shows that bone fracture is costly in this
